Skip to main content
. 2018 Oct 15;119(8):915–921. doi: 10.1038/s41416-018-0269-5

Table 2.

Baseline characteristics of the included patients

Total cohort (n = 114), n (%) No VTE recurrence (n = 104), n (%) VTE recurrence (n = 10), n (%)
Age, mean ± SD (years) 61.7 ± 13.7 61.8 ± 13.7 59.9 ± 14.3
Male, n (%) 58 (51.3) 51 (50) 7 (70)
Haematological cancer, n (%) 16 (14.3) 14 (13.9) 2 (20)
Solid tumour, n (%)
  Breast 20 (17.9) 18 (17.8) 2 (20)
  Colorectal 20 (17.9) 20 (19.8) 0 (0)
  Lung 12 (10.7) 9 (8.9) 3 (30)
  Prostate 9 (8) 9 (7.9) 1 (10)
  Bladder 6 (5.4) 6 (5.9) 0 (0)
  Kidney 3 (2.7) 2 (2) 1 (10)
  Pancreas 2 (1.8) 1 (1) 1 (10)
  Brain 2 (1.8) 2 (2) 0 (0)
  Others 22 (19.6) 21 0
Metastasis 45 (39.8) 39 (37.9) 6 (60)
ECOG performance status, n (%)
  0 56 (49.1) 52 (50.5) 4 (40)
  1 51 (44.7) 46 (44.5) 5 (50)
  2 3 (2.6) 3 (2.9) 0 (0)
  3 1 (0.9) 1 (1) 0 (0)
  4 3 (2.6) 2 (1.9) 1 (10)
VTE presentation, n (%)
  DVT 61 (53.5) 55 (53.4) 6 (60)
  PE 33 (28.9) 33 (32) 0 (0)
  DVT+PE 13 (11.4) 9 (8.6) 4 (40)
  Atypical VTE location 7 (6.1) 7 (6.8) 0 (0)
Incidental VTE, n (%) 33 (29) 33 (32) 0 (0)
VTE recurrence 10 (8.8)
Death 10 (8.8) 6 (5.9) 2 (20)

VTE venous thromboembolism, SD standard deviation, ECOG Eastern Cooperative Oncology Group, DVT deep vein thrombosis, PE pulmonary embolism